Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | SVP, Chief Tech. Ops. Officer | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,341 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 1,650 · Balance 20,341 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 19,544 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 797 · Balance 19,544 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 1,650 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 21:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000014 · wk-form4_1786741823.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F3 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 797 | $46.57 | $37,116.29 |
DisclosureSEC source: 0001804567-26-000014 · wk-form4_1786741823.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,544 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 21:10 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000014 · wk-form4_1786741823.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 21:05 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000012 · wk-form4_1785531908.xml · derivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,650 Underlying: Common Stock · 1,650 shares Expires not disclosed F1 · derivative.exercise_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. F1 · derivative.expiration_date: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 20:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 1,623 | $53.65 | $87,073.95 |
DisclosureSEC source: 0001804567-26-000010 · wk-form4_1773173598.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,440 Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000010 · wk-form4_1773173598.xml · derivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,793 | $54.73 | $98,130.89 |
DisclosureSEC source: 0001804567-26-000010 · wk-form4_1773173598.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,063 F1 · kind: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:13 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000010 · wk-form4_1773173598.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:09 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000008 · wk-form4_1772572184.xml · derivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000006 · wk-form4_1772140796.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 977 | $50.69 | $49,524.13 |
DisclosureSEC source: 0001804567-26-000006 · wk-form4_1772140796.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,106 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000006 · wk-form4_1772140796.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,083 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · derivative · entry 9 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · derivative · entry 8 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · derivative · entry 7 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,375 Underlying: Common Stock · 1,125 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 670 | $50.86 | $34,076.20 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,208 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,878 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 368 | $50.86 | $18,716.48 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,628 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,996 Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 603 | $51.35 | $30,964.05 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,246 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 24, 2026 Filed Feb 25, 2026 21:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000004 · wk-form4_1772056473.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,849 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:46 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001804567-26-000002 · wk-form4_1771624006.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:46 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $50.20 | $0.00 |
DisclosureSEC source: 0001804567-26-000002 · wk-form4_1771624006.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2036-02-18 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 18, 2027. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · derivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 24, 2018. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · derivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019 . Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $50.47 | $757,050.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,496 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.69. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $25.30 | $379,500.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $50.22 | $251,100.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,496 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.39. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $39.40 | $197,000.00 |
DisclosureSEC source: 0001628280-25-058506 · wk-form4_1766437463.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2025. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019 . Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $45.87 | $229,350.00 |
DisclosureSEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,496 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.73 to $45.96. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| September 12, 2025 Filed Sep 15, 2025 21:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $39.40 | $197,000.00 |
DisclosureSEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 14,000 | $44.51 | $623,140.00 |
DisclosureSEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,496 F2 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 1, 2026. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:59 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 14,000 | $12.98 | $181,720.00 |
DisclosureSEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 21:34 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 2,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011325 · wk-form4_1741383241.xml · derivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F3 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 21:34 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,356 | $39.11 | $53,033.16 |
DisclosureSEC source: 0001628280-25-011325 · wk-form4_1741383241.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,151 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| March 07, 2025 Filed Mar 7, 2025 21:34 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-011325 · wk-form4_1741383241.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 17, 2025. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 945 | $33.05 | $31,232.25 |
DisclosureSEC source: 0001628280-25-010472 · wk-form4_1741209547.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,882 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 610 | $33.05 | $20,160.50 |
DisclosureSEC source: 0001628280-25-010472 · wk-form4_1741209547.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,827 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 21:19 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 337 | $33.05 | $11,137.85 |
DisclosureSEC source: 0001628280-25-010472 · wk-form4_1741209547.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,437 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · derivative · entry 6 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 2,010 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · derivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F2 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,909 | $39.48 | $75,367.32 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · nonDerivative · entry 4 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,774 F1 · price: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · nonDerivative · entry 3 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 976 | $39.48 | $38,532.48 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · nonDerivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,933 F1 · price: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| February 26, 2025 Filed Feb 26, 2025 22:56 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008262 · wk-form4_1740610595.xml · nonDerivative · entry 1 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · derivative · entry 9 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,875 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F7 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F7 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · nonDerivative · entry 5 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,899 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:18 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007528 · wk-form4_1740446308.xml · derivative · entry 8 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F6 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F6 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.